Peking University
Clinical trials sponsored by Peking University, explained in plain language.
-
Engineered immune cells take on Hard-to-Treat gut cancers
Disease control TerminatedThis early-phase study tested a new treatment called LCAR-G08, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells in the gut. The study included 17 adults with advanced colorectal, stomach, pancreatic, or small bowel …
Phase: PHASE1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Bile duct cancer trial halted after just one patient
Disease control TerminatedThis phase II trial tested a combination of chemotherapy infused directly into the liver (HAIC) plus two immunotherapy drugs (atezolizumab and bevacizumab) given before and after surgery for high-risk bile duct cancer. The goal was to see if this approach could shrink tumors and …
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Liver cancer combo trial halted early – only 18 patients enrolled
Disease control TerminatedThis study tested whether adding a stronger chemotherapy infusion (HAIC-TACE) to the targeted drug donafenib works better than standard treatment for people with intermediate-stage liver cancer that cannot be removed by surgery. The trial was stopped early and only included 18 pa…
Phase: PHASE2, PHASE3 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC